BioNTech SE (BNTX) EBT Margin (2018 - 2026)
BioNTech SE (BNTX) posted EBT Margin of 25.06% for Q4 2025, down 1641.08% sequentially from 1.63% in Q3 2025, and down 2507.0% YoY from 1.04% in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) EBT Margin (2018 - 2026) Analysis & Trends
BioNTech SE has reported EBT Margin for 8 years, with the latest figure at 25.06% in Q4 2025.
- Quarterly EBT Margin fell 2507.0% year-over-year to 25.06% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 34.95% (down 3493.0% YoY) and the FY2025 annual result came in at 36.61%, down 1198.0% from the prior year.
- EBT Margin declined to 25.06% in Q4 2025 per BNTX's latest filing, from 1.63% in the prior quarter.
- Over five years, EBT Margin peaked at 85.2% in Q4 2021 and troughed at 626.11% in Q2 2024.
- A 5-year average of 35.9% and a median of 35.12% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin slumped 38031 bps in 2024, then surged 47170 bps in 2025.
- Over 5 years, EBT Margin stood at 85.2% in 2021, then dropped by 13 bps to 74.16% in 2022, then tumbled by 40 bps to 44.84% in 2023, then slumped by 100 bps to 0.01% in 2024, then sank by 274668 bps to 25.06% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 25.06%, 1.63%, and 154.41% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | -813.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -813.16% |
| Mar 31, 2026 | -481.03% |
| Dec 31, 2025 | -25.06% |
| Sep 30, 2025 | 1.63% |
| Jun 30, 2025 | -154.41% |
| Mar 31, 2025 | -243.65% |
| Dec 31, 2024 | 25.31% |
| Sep 30, 2024 | 12.75% |
| Jun 30, 2024 | -626.11% |
| Mar 31, 2024 | -176.87% |
| Dec 31, 2023 | 44.84% |
| Sep 30, 2023 | 25.40% |
| Jun 30, 2023 | -245.80% |
| Mar 31, 2023 | 55.42% |
| Dec 31, 2022 | 74.16% |
| Sep 30, 2022 | 70.61% |
| Jun 30, 2022 | 72.56% |
| Mar 31, 2022 | 78.72% |
| Dec 31, 2021 | 85.20% |
| Sep 30, 2021 | 76.67% |